Envoy Medical implemented a 1-for-10 reverse stock split of its Class A common stock, which became effective on October 26, 2026. The action was authorized by shareholders at a special meeting on October 12, 2026, and approved by the board to maintain compliance with Nasdaq's $1.00 minimum bid price requirement. Every ten outstanding shares were combined into one share, with fractional shares paid out in cash. Exercise prices for warrants and convertible securities, as well as terms of stock incentive plans, were proportionately adjusted. The company operates in the hearing health and neuroprosthetics sector, developing fully implanted hearing solutions.
